CTOs on the Move

Dialyze Direct

www.dialyzedirect.com

 
Dialyze Direct provides staff assisted home hemodialysis services to elderly patients with End Stage Renal Disease who reside in Nursing Homes. Our mission is to deliver innovative and compassionate dialysis care to geriatric patients in Skilled Nursing Facilities, enhancing their quality of life while significantly reducing overall costs by improving outcomes, eliminating transportation and minimizing re-hospitalizations. The Dialyze Direct program permits an unprecedented degree of on-site coordination of care and sharing information with the nursing home staff, with respect to ESRD care, that include nursing, dietary and social work collaboration. Dialyze Direct has re-purposed home dialysis technology, with enhanced ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Solomon Rubinfeld
Chief Operating Officer of SNF Division Profile

Similar Companies

Sonoma Orthopedic Products Inc

Sonoma Orthopedic Products Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Vascular Insights

Vascular Insights is a Quincy, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hillhouse Capital Management

Hillhouse Capital Management is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scrubs AC

Scrubs AC is a Calabasas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insulet

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.